跳至主要内容
临床试验/NCT01575158
NCT01575158已完成不适用

Citalopram vs Clomipramine vs Placebo in Recurrent Depression

University of Aarhus0 个研究点目标入组 59 人开始时间: 1997年10月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
入组人数
59
主要终点
2 Hamilton Depression Rating Scale scores of at least 16 with one weeks interval or initiation of another antidepressant treatment

研究概览

简要总结

citalopram and clomipramine are better than placebo in preventing new episodes of depression in patients with recurrent depression

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients with recurrent depression
  • Sustained response achieved (3 consecutive monthly ratings at the HDS below 13)after a treatment requiring index episode

排除标准

  • Contraindications to study medications
  • Pregnancy
  • Substance abuse

研究组 & 干预措施

citalopram

Experimental

citalopram

干预措施: Citalopram (Drug)

clomipramnine

Active Comparator

clomipramine

干预措施: Clomipramine (Drug)

placebo

Placebo Comparator

placebo

干预措施: placebo (Drug)

结局指标

主要结局

2 Hamilton Depression Rating Scale scores of at least 16 with one weeks interval or initiation of another antidepressant treatment

时间窗: 2 years of follow-up

次要结局

  • Study termination due to adverse event or non-compliance(2 years of follow-up)

研究者

申办方类型
Other
责任方
Sponsor

相似试验